PD-1 pathway inhibitors: Changing the landscape of cancer immunotherapy

Keyphrases

• Pathway Inhibitors 100%
• Cancer Immunotherapy 100%
• Programmed Death-ligand 1 (PD-L1) 100%
• Programmed death-1 Pathway 100%
• Anti-PD-1 80%
• Anti-programmed Death 1 80%
• Tumor 60%
• Hematological Malignancies 20%
• Durable Response 20%
• Therapeutic Target 20%
• Solid Tumors 20%
• Drug Development 20%
• Lung Cancer 20%
• Signaling Pathway 20%
• Targeted Therapy 20%
• Poor Prognosis 20%
• Cytotoxic Chemotherapy 20%
• Cancer Treatment 20%
• Oncology 20%
• Tumor Malignancy 20%
• Immunotherapeutics 20%
• Comprehensive Literature Review 20%
• Safety Profile 20%
• Melanoma 20%
• Checkpoint Inhibitors 20%
• Kidney Cancer 20%
• Checkpoint Inhibitor Therapy 20%
• American Society of Clinical Oncology 20%
• MEDLINE 20%
• Immunotherapeutic Approaches 20%
• PubMed 20%
• Good Safety 20%
• Checkpoint Activation 20%
• Stopping Therapy 20%
• Early Clinical Exposure 20%
• Tumor-induced Immune Suppression 20%
• Pathways in Cancer 20%
• Immune Destruction 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Neoplasm 100%
• Immunotherapy 100%
• Drug Development 25%
• Cytotoxic Chemotherapy 25%
• Solid Malignant Neoplasm 25%
• Lung Cancer 25%
• Hematologic Malignancy 25%
• Melanoma 25%
• Programmed Death 1 Receptor 25%
• Kidney Cancer 25%

Medicine and Dentistry

• Checkpoint Signalling 14%